BEIJING, Oct. 28, 2025 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated platforms at the 2025 Festival of Biologics in Basel. Over 2,000 biotech experts from 50 countries attended, witnessing Tsingke's AI-driven solutions for gene and RNA design, antibody discovery, and scalable GMP-grade biologics production, highlighting the company's role in bridging laboratory research with industrial-scale manufacturing.
Industry Trends Highlighted:
- Early-stage developability: process validation begins during discovery
- Data-driven design: AI and NGS redefine antibody and protein engineering
- Multimolecular integration: ADCs, PROTACs, and AOCs reshape biologics
"The boundary between research and manufacturing is fading — scientists are validating manufacturability in the lab, while industry adopts results faster than ever," said Nan Zhang, Marketing Manager of Tsingke Biotech.
Tsingke's Perspective: From Gene Synthesis to Scalable Manufacturing
As a full-stack Gene Factory, Tsingke Biotech demonstrated capabilities spanning DNA/RNA synthesis, antibody expression, and nucleic acid process development. Its integrated platform connects discovery with scalable production, enabling a smooth transition from innovation to industrial manufacturing.
Tsingke's Capabilities:
- High-throughput gene synthesis and modified primers for epitope mapping
- Chemically modified oligos and conjugation modules for ADC/PROTAC/AOC R&D
- Optimized nucleic acid purification and LNP encapsulation for process translation
Together, these capabilities position Tsingke to respond to emerging trends and advance next-generation biologics.
Guided by its vision, "The Great Tsingke Gene Factory," the company advances biomanufacturing through automation, digital design, and precision synthesis. "The Festival of Biologics bridges scientific breakthroughs and industrial application," added Nan Zhang.
About Tsingke
Beijing Tsingke Biotech Co., Ltd. is a leading biotechnology company providing comprehensive solutions for research and therapeutic development. With expertise in molecular biology, genetics, and protein science, Tsingke offers custom DNA/RNA synthesis, gene cloning, protein expression, antibody discovery, and viral vector packaging (AAV, LV, AdV). Its ISO 13485–certified facilities and Class 100,000 cleanroom ensure consistent quality and reliability. Backed by advanced automation and a global scientific team, Tsingke accelerates innovation in drug discovery, functional genomics, and genetic engineering—empowering researchers worldwide with cutting-edge biomanufacturing solutions.
For news and updates, follow Tsingke Biotech on LinkedIn.
Contact: market@tsingke.com.cn
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics
LAS VEGAS, Jan. 17, 2026 /PRNewswire/ -- At CES 2026, Flowtica was not the loudest presence on the show floor. Over the course of the week, however, the Singapore-based AI company became one of the most closely watched, drawing sustained attention from media, investors, and industry observers.
That attention has now translated into availability. Following its appearance as a CES 2026 Innovation Award Honoree, Flowtica has officially opened sales of Flowtica Scribe, its AI recording pen that quietly stood out in a field dominated by phone-dependent and screen-heavy solutions.
Flowtica Scribe did not make its first public appearance at CES. The product launched on Kickstarter several months earlier, where it attracted thousands of users and established early validation. CES marked a different stage for the company. The focus shifted away from introduction and toward closer examination, with many observers asking whether the idea could hold up beyond early enthusiasm.
Throughout the exhibition, Flowtica's booth at Eureka Park became a steady meeting point for investors and journalists. Conversations rarely centered on specifications or feature lists. Instead, discussions focused on a more fundamental question: whether AI recording tools are beginning to converge on forms that genuinely fit into professional life.
Flowtica's answer was visible in its choice of form. By embedding AI into a pen, an object already accepted in boardrooms, consultations, investor meetings, and sales conversations, the company avoided many of the social and practical frictions that continue to limit phone-based recorders. The result was a device that felt less like a new category of gadget and more like a natural extension of existing behavior.
This restraint is deliberate. Flowtica Scribe is designed to remain unobtrusive, with no screen and no demand for user attention during conversations. Recording, organization, and interpretation take place quietly in the background, allowing users to remain focused on the discussion itself. Among on-site observers, this approach positioned Flowtica as one of the more pragmatic entrants in an increasingly crowded AI recording market.
Hardware, however, represents only part of Flowtica's differentiation. The company places equal emphasis on what happens after recording ends. Its AI functions as a continuously evolving insight system that can operate autonomously while remaining responsive to clear user guidance when needed. Over time, it adapts to individual working rhythms and priorities, shifting the emphasis from capturing everything to identifying what truly matters.
Rather than simply storing conversations, Flowtica helps determine which moments should be retained, revisited, and translated into next actions. Key insights are designed to integrate naturally with existing productivity tools, including calendars and task systems, allowing them to fit into established workflows rather than compete with them.
As interest in Flowtica Scribe built during CES, one question surfaced repeatedly. When would the product be available beyond the show floor?
With sales now officially open through Flowtica's website, the company moves from exhibition attention to real-world deployment. For Flowtica, this moment appears less like a conclusion and more like a transition, from being observed to being used.
As the AI recording market continues to mature, competition is shifting away from novelty and early adoption toward durability. The defining question is no longer whether a system can record conversations, but whether it can remain useful over time.
Flowtica enters this next phase with an approach that is measured and quietly confident, placing its bet not on spectacle, but on long-term relevance.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
The AI Recording Pen That Turned Heads at CES Is Finally for Sale
